|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FERMT2 |
Gene summary for FERMT2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FERMT2 | Gene ID | 10979 |
| Gene name | FERM domain containing kindlin 2 | |
| Gene Alias | KIND2 | |
| Cytomap | 14q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q96AC1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10979 | FERMT2 | P130T-E | Human | Esophagus | ESCC | 1.50e-56 | 1.23e+00 | 0.1676 |
| 10979 | FERMT2 | NAFLD1 | Human | Liver | NAFLD | 6.51e-03 | 5.51e-01 | -0.04 |
| 10979 | FERMT2 | S43 | Human | Liver | Cirrhotic | 4.62e-07 | -1.81e-01 | -0.0187 |
| 10979 | FERMT2 | HCC1_Meng | Human | Liver | HCC | 1.60e-43 | -8.92e-02 | 0.0246 |
| 10979 | FERMT2 | HCC2_Meng | Human | Liver | HCC | 6.69e-07 | -2.79e-01 | 0.0107 |
| 10979 | FERMT2 | Pt13.b | Human | Liver | HCC | 5.34e-07 | 2.05e-01 | 0.0251 |
| 10979 | FERMT2 | S014 | Human | Liver | HCC | 9.76e-09 | 6.84e-01 | 0.2254 |
| 10979 | FERMT2 | S015 | Human | Liver | HCC | 1.97e-05 | 6.40e-01 | 0.2375 |
| 10979 | FERMT2 | S016 | Human | Liver | HCC | 1.29e-07 | 6.06e-01 | 0.2243 |
| 10979 | FERMT2 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 1.49e-07 | 9.95e-01 | -0.2247 |
| 10979 | FERMT2 | GSM5252133_BPH389PrSF | Human | Prostate | BPH | 2.95e-03 | 6.22e-01 | -0.2027 |
| 10979 | FERMT2 | 047563_1562-all-cells | Human | Prostate | BPH | 5.22e-15 | -9.89e-03 | 0.0791 |
| 10979 | FERMT2 | 048752_1579-all-cells | Human | Prostate | BPH | 5.02e-24 | 6.47e-01 | 0.1008 |
| 10979 | FERMT2 | 052097_1595-all-cells | Human | Prostate | BPH | 5.13e-12 | 4.53e-01 | 0.0972 |
| 10979 | FERMT2 | 052099_1652-all-cells | Human | Prostate | BPH | 1.05e-08 | 4.13e-01 | 0.1038 |
| 10979 | FERMT2 | Dong_P1 | Human | Prostate | Tumor | 5.85e-16 | -3.21e-01 | 0.035 |
| 10979 | FERMT2 | Dong_P3 | Human | Prostate | Tumor | 1.57e-06 | -3.58e-01 | 0.0278 |
| 10979 | FERMT2 | Dong_P5 | Human | Prostate | Tumor | 7.26e-17 | -3.58e-01 | 0.053 |
| 10979 | FERMT2 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 4.36e-04 | -3.73e-01 | 0.1575 |
| 10979 | FERMT2 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 5.97e-08 | -3.37e-01 | 0.1545 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003450418 | Esophagus | ESCC | protein localization to nucleus | 211/8552 | 290/18723 | 4.06e-21 | 6.60e-19 | 211 |
| GO:1903829111 | Esophagus | ESCC | positive regulation of cellular protein localization | 199/8552 | 276/18723 | 2.99e-19 | 3.45e-17 | 199 |
| GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
| GO:0031334111 | Esophagus | ESCC | positive regulation of protein-containing complex assembly | 166/8552 | 237/18723 | 2.06e-14 | 1.07e-12 | 166 |
| GO:190018018 | Esophagus | ESCC | regulation of protein localization to nucleus | 102/8552 | 136/18723 | 2.84e-12 | 1.13e-10 | 102 |
| GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
| GO:190018217 | Esophagus | ESCC | positive regulation of protein localization to nucleus | 70/8552 | 87/18723 | 2.63e-11 | 8.99e-10 | 70 |
| GO:1902905111 | Esophagus | ESCC | positive regulation of supramolecular fiber organization | 142/8552 | 209/18723 | 5.51e-11 | 1.76e-09 | 142 |
| GO:1902903111 | Esophagus | ESCC | regulation of supramolecular fiber organization | 237/8552 | 383/18723 | 9.06e-11 | 2.75e-09 | 237 |
| GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
| GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
| GO:0150115110 | Esophagus | ESCC | cell-substrate junction organization | 77/8552 | 101/18723 | 3.46e-10 | 9.57e-09 | 77 |
| GO:000704418 | Esophagus | ESCC | cell-substrate junction assembly | 73/8552 | 95/18723 | 5.27e-10 | 1.35e-08 | 73 |
| GO:005149520 | Esophagus | ESCC | positive regulation of cytoskeleton organization | 147/8552 | 226/18723 | 2.93e-09 | 6.38e-08 | 147 |
| GO:003158919 | Esophagus | ESCC | cell-substrate adhesion | 221/8552 | 363/18723 | 3.06e-09 | 6.62e-08 | 221 |
| GO:001081020 | Esophagus | ESCC | regulation of cell-substrate adhesion | 144/8552 | 221/18723 | 3.55e-09 | 7.45e-08 | 144 |
| GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
| GO:004804116 | Esophagus | ESCC | focal adhesion assembly | 65/8552 | 87/18723 | 3.28e-08 | 6.08e-07 | 65 |
| GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
| GO:0032970111 | Esophagus | ESCC | regulation of actin filament-based process | 231/8552 | 397/18723 | 2.91e-07 | 4.20e-06 | 231 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FERMT2 | SNV | Missense_Mutation | novel | c.1513N>T | p.Pro505Ser | p.P505S | Q96AC1 | protein_coding | tolerated(0.31) | benign(0.012) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FERMT2 | SNV | Missense_Mutation | c.1900N>C | p.Glu634Gln | p.E634Q | Q96AC1 | protein_coding | tolerated(0.64) | possibly_damaging(0.677) | TCGA-C8-A1HF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FERMT2 | insertion | Frame_Shift_Ins | novel | c.1909_1910insGGCTTAACCTATATGAACTCTATTTATCATGTCTA | p.Asp637GlyfsTer24 | p.D637Gfs*24 | Q96AC1 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| FERMT2 | deletion | Frame_Shift_Del | novel | c.55delN | p.Glu19AsnfsTer2 | p.E19Nfs*2 | Q96AC1 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| FERMT2 | SNV | Missense_Mutation | c.1095T>G | p.Ile365Met | p.I365M | Q96AC1 | protein_coding | tolerated(0.29) | possibly_damaging(0.653) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FERMT2 | SNV | Missense_Mutation | c.997N>C | p.Glu333Gln | p.E333Q | Q96AC1 | protein_coding | tolerated(0.5) | benign(0.291) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FERMT2 | SNV | Missense_Mutation | c.720A>T | p.Gln240His | p.Q240H | Q96AC1 | protein_coding | deleterious(0.02) | possibly_damaging(0.871) | TCGA-A6-4105-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| FERMT2 | SNV | Missense_Mutation | c.1997N>A | p.Arg666His | p.R666H | Q96AC1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3509-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FERMT2 | SNV | Missense_Mutation | c.1316T>G | p.Phe439Cys | p.F439C | Q96AC1 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AA-3851-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FERMT2 | SNV | Missense_Mutation | c.106A>G | p.Thr36Ala | p.T36A | Q96AC1 | protein_coding | tolerated(0.35) | benign(0.108) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |